| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2289SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-167SS | |||
| Azide and BSA Free | NBP2-80826 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-616SS | |||
| Azide and BSA Free | NBP2-80820 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-06640SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56694SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-125SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27293SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77461SS | |||
![Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AHR-Antibody-Knockdown-Validated-NB100-2289-img0014.jpg "<b>Genetic Strategies Validation. </b>Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: AHR Antibody [NB100-2289] - Staining of Aryl hydrocarbon Receptor in mouse prostate.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-NB100-2289-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-AHR at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0012.jpg)
![Western Blot: AHR Antibody [NB100-2289] - Detection of AhR in mouse liver cytosol using NB 100-2289.](http://images.novusbio.com/fullsize/AHR-Antibody-Western-Blot-NB100-2289-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HepG2 cells were fixed for 10 minutes using 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-AHR at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0015.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U937 cells with NB100-2289 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - Aryl hydrocarbon Receptor antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0010.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U-87 cells with AHR Antibody NB100-2289B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0013.jpg)
![Simple Western: AHR Antibody [NB100-2289] - Image shows a specific band for Aryl hydrocarbon receptor in 0.5 mg/mL of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/AHR-Antibody-Simple-Western-NB100-2289-img0011.jpg)
![Western Blot: AHR Antibody - BSA Free [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha . (A) qPCR to detect mRNA level of CYP1A1, NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells (upper part) & T47D cells (lower part). Relative expression level of CYP1A1 is shown in log2 scale; relative expression level of NQO1, HO1 & TRXR1 are shown as fold change, both normalized with DMSO treatment. All values represent the mean ± SD of two times independent experiments performed in three replicates. (B) Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) & western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean ± SD of two independent experiments performed in three replicates. (C) DCF-DA staining of ROS levels upon doxorubicin treatment (1 µM, 8 h) with or without PFT-alpha (20 µM, 12 h pre-treatment) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. For quantification of ROS levels (lower panel), the values are reported as percentage relative to DMSO treatment group. (D) qPCR to detect mRNA level of Nrf2 targets NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31974452), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2289_rabbit-polyclonal-ahr-antibody-3102024165720.jpg)
![Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from TCMK-1 and NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Western-Blot-NB100-215-img0009.jpg "Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from TCMK-1 and NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: Menin Antibody [NB100-215] - Section of human lung carcinoma. Antibody: Affinity purified rabbit anti-Menin used at a dilution of 1:1,000 (1ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/Menin-Antibody-Immunohistochemistry-Paraffin-NB100-215-img0010.jpg)
![Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from HeLa, HEK293T, and Jurkat cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Western-Blot-NB100-215-img0008.jpg)
![Immunoprecipitation: Menin Antibody [NB100-215] - Detection of human Menin by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Menin antibody NB100-215 (lot 2) used for IP at 6 ug per reaction. Menin was also immunoprecipitated by a previous lot of this antibody (lot 1). For blotting immunoprecipitated Menin, NB100-215 was used at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Immunoprecipitation-NB100-215-img0007.jpg)
![Western Blot: KAP1 Antibody [NB500-158] - Whole cell lysate (50 ug) from NIH 3T3, TCMK-1, 4T1, CT26.WT, and rat C6 cells. Antibodies: Affinity purified rabbit anti-KAP-1 antibody used for WB at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/KAP1-Antibody-Western-Blot-NB500-158-img0028.jpg "Western Blot: KAP1 Antibody [NB500-158] - Whole cell lysate (50 ug) from NIH 3T3, TCMK-1, 4T1, CT26.WT, and rat C6 cells. Antibodies: Affinity purified rabbit anti-KAP-1 antibody used for WB at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![Immunohistochemistry-Paraffin: KAP1 Antibody [NB500-158] - FFPE sections of human breast carcinoma. KAP1 antibody Lot3 (left) and Lot2 (right) used at a dilution of 1:1000 (1 ug/mL). Detection: DAB.](http://images.novusbio.com/fullsize/KAP1-Antibody-Immunohistochemistry-NB500-158-img0022.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: KAP1 Antibody [NB500-158] - Detection of Human KAP1 by Western blot. Whole cell lysate from HeLa (5, 15 and 50 ug), and 293T (50 ug) cells. KAP1 antibody at 0.1 ug/mL. Detection by chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/KAP1-Antibody-Western-Blot-NB500-158-img0024.jpg)
![Western Blot: KAP1 Antibody [NB500-158] - Hep3B human hepatocellular carcinoma cell line. 50 ug cell lysate per lane. 10% SDS-PAGE. KAP1 (TRIM28) antibody at 1:1000 dilution in 5% milk at 4C O/N. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KAP1-Antibody-Western-Blot-NB500-158-img0025.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: KAP1 Antibody [NB500-158] - Detection of human KAP-1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from HeLa cells. Antibodies: Affinity purified rabbit anti-KAP-1 antibody NB500-158 (lot NB500-158-3) used for IP at 6 ug/mg lysate. KAP-1 was also immunoprecipitated by a previous lot of this antibody (lot NB500-158-2) and rabbit anti-KAP-1 antibody NB500-159. For blotting immunoprecipitated KAP-1, NB500-158 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/KAP1-Antibody-Immunoprecipitation-NB500-158-img0026.jpg)
![Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)](http://images.novusbio.com/fullsize/LANA2-Antibody-CM-A807-Western-Blot-NB200-167-img0003.jpg "Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)")
![Immunohistochemistry-Paraffin: LANA2 Antibody (CM-A807) [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource and performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA. Representative image shows the LANA staining of skin KS lesion. Image collected and cropped by CiteAb from the following publication (//mbio.asm.org/lookup/doi/10.1128/mBio.02217-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LANA2-Antibody-CM-A807-Immunohistochemistry-Paraffin-NB200-167-img0004.jpg)
![Immunohistochemistry: LANA2 Antibody (CM-A807) - BSA Free [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource & performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA & anti-vIRF3 (CM-A807). Representative images show the LANA staining of skin KS lesion & the vIRF3 staining of skin, tonsil, & mouth KS lesions & positive staining corresponding to either LANA or vIRF3 in total KS biopsy specimens embedded in TMA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29339432), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-167_mouse-monoclonal-lana2-antibody-cm-a807-310202415371954.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0005.jpg "Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.")
![Western Blot: KAT3B/p300 Antibody (RW105) [NB100-616] - p300 detected in a HeLa nuclear extract using NB 100-616 (1:250). ECL: 20 minute exposure.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Western-Blot-NB100-616-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B/p300 Antibody (RW105) NB100-616 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0008.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on RAW 246.7 cells with KAT3B/p300 antibody (RW105) NB100-616PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin. Image using the PE format of this antibody.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0006.jpg)
![Flow (Intracellular): KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on THP-1 cells with KAT3B/p300 (RW105) antibody NB100-616 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% Saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Intracellular-NB100-616-img0003.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on Raw264.7 cells with KAT3B/p300 Antibody (RW105) NB100-616 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: KAT3B/p300 Antibody (RW105) [NB100-616] - 293T cells were treated with different siRNAs against p300 alone for 2 days and core histones were prepared and subjected to WB analysis as indicated. The knockdown efficiency of p300 was confirmed by WB analysis of cell lysates. Western Blot protocol is 6% gel for running, 40V overnight transfer membrane. primary Ab 1:500, secondary Ab 1:5000. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-616_mouse-monoclonal-kat3b-p300-antibody-rw105-knockdown-validated-147202311647.jpg)
![Western Blot: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody [NBP1-06640] - KDM6A protein levels are decreased following EMT and upregulated during MET. MCF10A cells, treated as described, were analyzed by immunoblotting for Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 and vimentin (Vim). COX IV was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/19214), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Lysine-K-specific-Demethylase-6B-KDM6B-JMJD3-Antibody-Western-Blot-NBP1-06640-img0007.jpg "<b>Biological Strategies Validation. </b>Western Blot: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody [NBP1-06640] - KDM6A protein levels are decreased following EMT and upregulated during MET. MCF10A cells, treated as described, were analyzed by immunoblotting for Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 and vimentin (Vim). COX IV was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/19214), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody [NBP1-06640] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-JMJD3 [NBP1-06640] at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) [NB100-690] was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Lysine-K-specific-Demethylase-6B-KDM6B-JMJD3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-06640-img0005.jpg)
![Western Blot: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody [NBP1-06640] - Analysis of JMJD3 expression on HepG2 whole cell lysates.](http://images.novusbio.com/fullsize/Lysine-K-specific-Demethylase-6B-KDM6B-JMJD3-Antibody-Western-Blot-NBP1-06640-img0004.jpg)
![Western Blot: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody [NBP1-06640] - Total protein from human HepG2 and mouse 3T3 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-JMJD3 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Lysine-K-specific-Demethylase-6B-KDM6B-JMJD3-Antibody-Western-Blot-NBP1-06640-img0006.jpg)
![Western Blot: Lysine (K)-specific Demethylase 6B/KDM6B/JMJD3 Antibody - BSA Free [NBP1-06640] - KDM6A protein levels are decreased following EMT & upregulated during MET(A) HMLE cells were transduced with either an empty vector (HMLE-Vector), or genes encoding the EMT-inducing transcription factors Snail (HMLE-Snail) or Twist (HMLE-Twist) [4]. Whole-cell lysates were analyzed by immunoblotting for KDM6A. beta -actin was used as a loading control. (B-F) MCF10A cells were treated with sterile 4 mM HCl containing 0.1% bovine serum albumin (Vehicle) or TGFB for 5 days (TGFB+). In parallel, MCF10A cells were exposed to TGFB for 5 days in order to induce EMT, & subsequently subjected to TGFB-withdrawal, for a further 5 days, to elicit MET (TGFB+/-). (B-C) MCF10A cells, treated as described, were fixed & immunostained for E-cadherin (B) & N-cadherin (C). Nuclei were counterstained with DAPI (blue). Scale bars, 50 μm. (D) MCF10A cells, treated as described, were analyzed by immunoblotting for KDM6B & vimentin (Vim). COX IV was used as a loading control. (E) MCF10A cells, treated as described, were fixed & immunostained for KDM6A. Nuclei were counterstained with DAPI (blue). Scale bars, 50 μm. (F) Cells were analyzed by immunoblotting for KDM6A, EZH2 & RING1A. beta -actin was used as a loading control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.19214), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-06640_rabbit-polyclonal-lysine-k-specific-demethylase-6b-kdm6b-jmjd3-antibody-310202416163738.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0021.jpg "Western Blot: FOXO3 Antibody [NBP2-16521] - FoxO3 expression in nuclear and cytosolic fraction of human breast cancer cell line MDA-MB-231. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: FOXO3 Antibody [NBP2-16521] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:1000. Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-16521-img0023.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse duodenum. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0028.jpg)
![<b>Genetic Strategies Validation. </b>Chromatin Immunoprecipitation (ChIP): FOXO3 Antibody [NBP2-16521] - (D) ChIP assay for LMOD1 and EGFR (as a positive control region) in HCASMC chromatin lysates immunoprecipitated with antibodies to FOXO3 or a negative control rabbit IgG. n = 3. (E) Allele specific ChIP (haploChIP) for FOXO3 protein in DNA derived from cultured HCASMC ChIP experiments. DNA from cell line homozygous for the ancestral allele was used as a positive control and arbitrarily set to 1. Values represent mean +/- standard deviation of triplicates. Similar results were observed from n = 4 independent lines for each genotype. (F) Quantitative RT-PCR analysis of LMOD1 in HCASMCs following knock down of endogenous FOXO3 (F) or overexpression of FOXO3 (G). The results were reproduced in n = 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1007755) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP2-16521-img0030.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - 50 ug of mouse brain whole cell lysate). Antibody at 1:500.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Western-Blot-NBP2-16521-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: FOXO3 Antibody [NBP2-16521] - Non-transfected (-) and transfected (+) C2C12 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Western-Blot-NBP2-16521-img0015.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Huh-7 xenograft, using FOXO3A antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/FOXO3A-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0003.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat colon. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0024.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse testis. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0025.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Rat brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-NBP2-16521-img0026.jpg)
![Immunohistochemistry-Paraffin: FOXO3 Antibody [NBP2-16521] - Mouse brain. FOXO3A stained by FOXO3A antibody [C3], C-term diluted at 1:2000. Antigen Retrieval: Citrate buffer, pH 6.0, 15 minutes.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunohistochemistry-Paraffin-Negative-NBP2-16521-img0027.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Jurkat whole cell lysate/extract A. Control with 2 ug of preimmune rabbit IgG B. Immunoprecipitation of FOXO3A protein by 2 ug of FOXO3A antibody 5% SDS-PAGE The immunoprecipitated FOXO3A protein was detected by FOXO3A antibody diluted at 1:1000. EasyBlot anti-rabbit IgG was used as a secondary reagent.](http://images.novusbio.com/fullsize/FOXO3-Antibody-Immunoprecipitation-NBP2-16521-img0029.jpg)
![Western Blot: FOXO3 Antibody [NBP2-16521] - LMOD1 expression is mediated by PDGF-BB-FOXO3 signaling cascade.(A) UCSC Browser screenshot of the LMOD1 CAD locus at chromosome 1q32.1 highlighting the candidate causal variant, rs34091558, overlapping ATAC-seq open chromatin & RNA-seq tracks in HCASMCs treated with PDGF-BB (n = 2 biological replicates). Genomic coordinates refer to hg19 assembly. Quantitative RT-PCR (B) & Western blotting (C) data revealing PDGF-BB & phosphorylated-FOXO3 (P-FOXO3) mediated LMOD1 expression. (D) Co-expression microarray analysis performed in a cohort of carotid atherosclerotic plaques (n = 127) indicating that LMOD1 & FOXO3 are positively correlated in arterial tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30444878), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202415345315.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p < 0.01, ***p < 0.001 vs. NTC/EV-V; #p < 0.05, ##p < 0.01 vs. NTC/EV-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C & E, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h. Cytosolic & nuclear lysates were prepared, & immunoblot assays were performed. F-H, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against H3K27me3 (F), H3K27ac (G), or Histone H3 (H) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-3102024161229.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - SMARCD3 knockdown blocks paclitaxel-induced FOXO3 binding on pluripotency factor genes & inhibits BCSC enrichment. A, MDA-MB-231 cells were transfected with vector encoding NTC or either of two shRNAs targeting SMARCD3 (#1 & #2), & immunoblot assay was performed. B-D, MDA-MB-231 NTC or SMARCD3 knockdown subclones were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h, & ALDH (B; mean ± SEM; n = 3), mammosphere (C; mean ± SEM; n = 4), & qPCR (D; mean ± SEM; n = 3) assays were performed; *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. E-I, MDA-MB-231 NTC or SMARCD3 knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against FOXO3 (E), H3K27me3 (F), H3K27ac (G), KDM6A (H), or p300 (I), followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 4); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202416114757.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - Chemotherapy-induced A2BR expression promotes FOXO3 binding on pluripotency factor genes through decreased H3K27me3 & increased H3K27ac chromatin marks. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h & chromatin immunoprecipitation (ChIP) was performed with antibody against FOXO3. Primers flanking the FOXO3 binding site in the NANOG, SOX2 & KLF4 gene (A) were used for qPCR (B; mean ± SEM; n = 3); **p < 0.01, ***p < 0.001 vs. NTC/EV-V; #p < 0.05, ##p < 0.01 vs. NTC/EV-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C & E, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h. Cytosolic & nuclear lysates were prepared, & immunoblot assays were performed. F-H, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or 10 nM P for 72 h. ChIP was performed using antibodies against H3K27me3 (F), H3K27ac (G), or Histone H3 (H) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. NTC-P; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-310202416121916.jpg)
![Immunoprecipitation: FOXO3 Antibody [NBP2-16521] - A2BR decreases H3K27me3 & increases H3K27ac marks through recruitment of KDM6A & p300 at FOXO3 binding sites of pluripotency factor genes. A & B, MDA-MB-231 NTC or A2BR knockdown subclones were transfected with pLX304 (empty vector, EV) or pLX304 encoding A2BR. Cells were treated with vehicle (V) or 10 nM paclitaxel (P) for 72 h. ChIP was performed using antibodies against KDM6A (A) or p300 (B) followed by qPCR with primers flanking FOXO3 binding sites in the NANOG, SOX2 & KLF4 gene (mean ± SEM; n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 vs. NTC-V; ##p < 0.01, ###p < 0.001 vs. NTC-P; ^^p < 0.01, ^^^p < 0.0001 vs. A2BR shRNA/EV-P; ns, not significant. C, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & immunoblot assays were performed. D, MDA-MB-231 NTC or A2BR knockdown subclones were treated with V or P for 72 h & nuclear lysates were prepared. Immunoprecipitation (IP) was performed using FOXO3 antibody or control IgG followed by immunoblot assays. NL, nuclear protein lysate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35401817), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-31020241612240.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: FOXO3 Antibody [NBP2-16521] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with FOXO3A antibody [C3], C-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp2-16521_rabbit-polyclonal-foxo3-antibody-1610202419405793.jpg)
![Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunoprecipitation-NB100-56694-img0006.jpg "Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.")
![Immunohistochemistry-Paraffin: TRF-2 Antibody [NB100-56694] - Analysis of Human Tonsil using TRF-2 antibody.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunohistochemistry-Paraffin-NB100-56694-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF-2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. One week post selection, +Dox cells were infected with HHV-6A for 48h and processed for IFA using anti-TRF-2 (green) and anti-IE2 (red). Cells with IE2 in punctate form and cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0008.jpg)
![Western Blot: TRF-2 Antibody [NB100-56694] - TRF2 knockdown affect HHV-6A/B chromosomal integration.A) U2OS cells were transduced with lentiviral vectors expressing a scrambles shRNA (shCtrl) or a shTRF2. After a week of selection, cells were monitored for TRF2 expression by western blot. B) After a week of selection, shCtrl & shTRF2 treated cells were infected with HHV-6A or HHV-6B. After 30 days, DNA was isolated & the relative frequency of integration, relative to shCtrl set at 100%, estimated by ddPCR. *p<0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415345328.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 expression in HHV-6A-infected U2OS cells.U2OS cells were infected with HHV-6A & analyzed for TRF2 & IE2 expression at 24h, 48h & 72h post-infection by dual color immunofluorescence. A) Representative immunofluorescence of TRF2 & IE2 expression in bystander & IE2 expressing cells at 24, 48h & 72h post infection. B) Mean relative TRF2 expression ± SD in uninfected (blue), IE2- (green-uninfected bystander) or IE2+ (red-infected) cells at 24h, 48h & 72h post infection. Each symbol represents the relative TRF2 expression from a single nucleus. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415304273.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-3102024155376.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 is required for IE2 localization with telomeres.U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF2 (shTRF2) & selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. B) One week post selection, +Dox cells were infected with HHV-6A for 48h & processed for IFA using anti-TRF2 (green) & anti-IE2 (red). Cells with IE2 in punctate form & cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. C) The percentage of HHV-6A infected cells (from B) was estimated after counting a minimum of 700 cells & scoring the IE2+ ones. Results are expressed as mean %IE2+ cells ± SD. D) Mean percentage ± SD of IE2 localizing with telomeres in the presence (shCtrl +Dox) & absence (shTRF2 +Dox) of TRF2. Each dot represents the % of IE2 foci localizing with telomeres in one nucleus. ****p<0.0001. E) IF-FISH confocal images of shCtrl (+Dox) & shTRF2 (+Dox) cells analyzed for TRF2 (green), IE2 (red) & telomeres (cyan). Nuclei are outlined by dashed circles. Examples of IE2 localizing with telomeres (top row) or not found with telomeres (bottom row) are highlighted by the dashed polygons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612657.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415523926.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - A) A stick diagram of the IE2 protein with various domains identified is presented. B) Colocalization of HHV-6A IE2 protein with telomeres in the absence of viral DNA. U2OS cells were transfected with an empty vector, with IE2 expression vector or with IE2 delta 1290–1500 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. Telomeres were labeled in cyan & IE2 in red. Nuclei are outlined by dashed lines. Examples of IE2 colocalizing with telomeres are presented in a 3D view (white arrows). C) The graph represents the mean ± SD % of WT IE2 & delta 1290–1500 IE2 localizing with telomeres. D) Lack of colocalization between HHV-6A p41 & telomeres in uninfected cells. U2OS cells were transfected with an empty vector or with a p41 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. TRF2 was labeled green, p41 in red & nuclei outlined by a dashed line. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415541930.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Colocalization of shelterin complex proteins & HHV-6A IE2 protein at VRC & cellular telomeres.A) U2OS cells were mock-infected or infected with HHV-6A for 48h after which cells were processed for IF-FISH. Telomeres were labeled in magenta, TRF2 in green & IE2 in red. The panels in the middle row show images of cells with IE2 patches overlapping with large, diffuse TRF2 & telomeric staining (rectangles). The panels in the third row represent infected cells with punctate IE2 pattern colocalizing with TRF2 & telomeres (dashed squares). The colocalization of IE2, TRF2 & telomeres are shown in both 2D & 3D images. B) Uninfected & HHV-6A-infected U2OS cells were transfected with an empty vector, a myc-tagged-TRF1 expression vector. Forty-eight hours later cells were processed for IF-FISH. TRF1 was labeled in green & IE2 in red. Nuclei were stained with DAPI. Images on the far right show 2D colocalization of TRF1 with IE2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612621.jpg)
![Western Blot: PER2 Antibody [NB100-125] - Western Blot Usage of NB100-125. Image submitted via verified customer review.](http://images.novusbio.com/fullsize/PER2-Antibody-Western-Blot-NB100-125-img0003.jpg "Western Blot: PER2 Antibody [NB100-125] - Western Blot Usage of NB100-125. Image submitted via verified customer review.")
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - U-87 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-PER2 Antibody at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0005.jpg)
![Western Blot: PER2 Antibody [NB100-125] - WB analysis of PER2 expression on ARPE-19 whole cell lysate.](http://images.novusbio.com/fullsize/PER2-Antibody-Western-Blot-NB100-125-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - The PER2 antibody was tested in ARPE-19 cells at a 1:250 dilution against Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: PER2 Antibody [NB100-125] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-PER2 Antibody at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/PER2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-125-img0004.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0005.jpg "Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of a FFPE tissue section of mouse placenta using 1:200 dilution of SNAIL antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0007.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - HER2 is overexpressed and both Herceptin incubation and siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells. Effects of Herceptin on levels of ZO1 and Snail. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0006.jpg)
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of in FFPE human kidney tissue using this antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0004.jpg)
![Simple Western: Snail Antibody [NBP2-27293] - Image shows a specific band for SNAIL in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Snail-Antibody-Simple-Western-NBP2-27293-img0002.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - SiRNAs against HER2 could abrogate the EMT phenotype & cell invasiveness in cisplatin-resistant gastric cancer cells.(A) Validation of silencing efficiency of HER2. Cells were transiently transfected with 50 nM HER2-specific siRNAs #1-#3 or a control siRNA for 48 h. (B) Knock-down of HER2 abrogated EMT morphology. Cells were transiently transfected with 50 nM specific siRNAs targeting HER2 for 48 h, Representative images of cellular morphology were shown. (C) Knock-down of HER2 abolished EMT phenotype. Cells were treated as in Fig. 4B. FITC-phalloidin staining of F-actin were performed & representative images were shown. (D) Effects of HER2 knock-down on the levels of ZO1 & Snail. (E) Effects of HER2 knock-down on cell migration. Representative images of transwell cell migration assay were shown. (F) Summary of Fig. 4E. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416114759.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - HER2 is overexpressed & both Herceptin incubation & siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells.(A) Western blot of HER2 in MGC803/DDP & AGS/DDP cell lines, & parental MGC803 & AGS cells. GAPDH was used as loading control. (B) Relative amplification of HER2 in parental & cisplatin-resistant cells. Results were presented as the mean ± SD of two independent experiments, *P < 0.05 compared with parental cells. (C) Herceptin incubation abrogated EMT morphology in MGC803/DDP cells. Representative images of cellular morphology of MGC803/DDP cells, plus parental MGC803 cells treated with Herceptin for 24 h were shown. Hercep represents Herceptin. (D) Herceptin incubation reversed EMT morphology in MGC803/DDP cells. Representative images of FITC-phalloidin staining of F-actin after 100 μg/ml Herceptin treatment for 24 h were shown. (E) Effects of Herceptin on levels of ZO1 & Snail. (F) CP724714 treatment abolished EMT-like cell morphology. Cells were incubated with 10 μM CP724714 for 24 h. Representative images of cellular morphology of were captured. (G) CP724714 treatment abrogated EMT-like cell morphology. Cells were treated as in Fig. 4F, FITC-phalloidin staining of F-actin was performed & typical images were shown. (H) Effects of CP724714 on ZO1 & Snail. (I) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Representative images were presented here. (J) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416113529.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0009.jpg "Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Vascularization of mineralized cell-laden collagen and interaction with prostate cancer cells. HUVECs formed endothelial networks that were supported by SMA-expressing hMSCs (scale bar: 50m) and were also positive for CD31 (scale bar: 400m). The remainder of hMSCs expressed RUNX2 as a marker for osteogenic differentiation (scale bar: 50m). Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31388010/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: RUNX2/CBFA1 Antibody [NBP1-77461] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with RUNX2/CBFA1 Antibody (NBP1-77461) at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-77461-img0010.jpg)
![Immunohistochemistry-Paraffin: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - RUNX2/CBFA1 Antibody [NBP1-77461] - Characterization of TLC cultured in chondrogenic pellets. Gene expression of TLC cultured four weeks in chondrogenic pellets or in cell monolayer in control medium: levels of expression of osteoblast markers (1), chondrocyte markers (2) and tenocyte markers (3) (N = 3) assessed by qPCR.* =0.05. Rotator Cuff Tenocytes Differentiate into Hypertrophic Chondrocyte-Like Cells to Produce Calcium Deposits in an Alkaline Phosphatase-Dependent Manner. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-Paraffin-NBP1-77461-img0008.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody [NBP1-77461] - Staining of RUNX2 in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/RUNX2-CBFA1-Antibody-Immunohistochemistry-NBP1-77461-img0006.jpg)
![Immunohistochemistry: RUNX2/CBFA1 Antibody - BSA Free [NBP1-77461] - Histological characterization of rotator cuff calcifications (N = 5). (A) Calcific deposits assessed by micro-computed tomography. (B) HE (hematoxylin & eosin) staining of decalcified samples (1 image for each patient). (C) Von Kossa staining on not decalcified samples & characterization of the fibrocartilaginous area with alcian blue staining, SOFG (Safranin O/Fast Green) staining, & immunohistochemical staining for COL2 (brown) with Gill hematoxylin counterstain. (D,E) Representative immunohistochemical staining for ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), TNAP (tissue non-specific alkaline phosphatase), Runx2, Sox9, Col10 & CD31 (brown). TF: tendon fibers; CD: calcium deposits, FM: fibrocartilaginous metaplasia; OM: osseous metaplasia; CT: connective tissue; V: vessels. Scale bar = 200 µM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31561454), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77461_rabbit-polyclonal-runx2-cbfa1-antibody-310202416154628.jpg)
![Immunocytochemistry/Immunofluorescence: MafA Antibody [NBP1-00121] - Analysis of MafA in 8-week old mouse pancretic cryosection using anti-MafA antibody (red). Image from verified customer review.](http://images.novusbio.com/fullsize/MafA-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-00121-img0003.jpg "Immunocytochemistry/Immunofluorescence: MafA Antibody [NBP1-00121] - Analysis of MafA in 8-week old mouse pancretic cryosection using anti-MafA antibody (red). Image from verified customer review.")
![Immunohistochemistry-Paraffin: MafA Antibody [NBP1-00121] - Section of mouse pancreatic islet. Antibody: Affinity purified rabbit anti-MafA (Cat. No. NBP1-00121) used at a dilution of 1:250.](http://images.novusbio.com/fullsize/MafA-Antibody-Immunohistochemistry-Paraffin-NBP1-00121-img0001.jpg)